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Lafora progressive myoclconus epilepsy, also known as
Lafora disease (LD), is the most severe and fatal form of
progressive myoclonus epilepsy with its typical onset
during the late childhood or early adolescence. LD is
characterised by the presence of abnormal glycogen
inclusions – called the polyglucosan bodies – in the neu-
rons and various other affected tissues. Therefore defects
in the glycogen metabolism have been suspected to
underlie neuropathology in LD. The two genes known
for LD have been extensively characterized; these are the
EPM2A and NHLRC1 genes, coding for a protein phos-
phatase (named laforin) and an E3 ubiquitin ligase
(named malin) respectively. Laforin and malin interact
with each other and as a complex participate in diverse
cellular pathways. The pathways include glycogen meta-
bolism, endoplasmic reticulum (ER) stress, ubiquitin-pro-
teasome pathways and in heat shock response. A number
of disease causing mutations, more than 100 of them,
are known in EPM2A and NHLRC1and several studies
have looked at possible genotype-phenotype correlations
in the LD families. The factors other than the defective
LD gene could possibly be involved in modifying the
disease onset or the progression in some cases. Indeed, a
recent study demonstrates that a sequence variant in the
PPP1R3C gene coding for the protein targeting to glycogen
(PTG) contributes to the milder course of LD. It would be
therefore important to check possible contributions of
sequence variations in critical regulators of these pathways
which interact with laforin and/or malin and test their pos-
sible role as modifiers in LD. Here we have extensively
reviewed the literature and list potential modifier genes for
LD, their cellular functions, and propose their possible
effect in LD. Validating these hypothesis will help us in
identifying “druggable targets” for delaying the onset and/
or the severity of LD if not its treatment.
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